Brought to you by 
Semma's Series B brings in $114mm
07 Dec 2017
Executive Summary
Three-year-old regenerative medicine firm Semma Therapeutics Inc. raised $114mm in an oversubscribed Series B financing co-led by Eight Roads Ventures and Cowen Healthcare Investments, which each add a board member and were joined by returning shareholders MPM Capital, F-Prime Capital Partners, Arch Venture Partners, Medtronic, and JDRF, partner Novartis, and first-time backers ORI Healthcare Fund, Wu Capital, 6 Dimensions Capital, and SinoPharm Capital. Semma will use the funds to move its encapsulated stem cell-derived islets program through clinical proof-of-concept for Type I diabetes.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Semma's Series B brings in $114mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice